Navigation Links
Mount Sinai Researchers Identify Mechanisms and Potential Biomarkers of Tumor Cell Dormancy
Date:10/27/2013

New York, NY (PRWEB) October 27, 2013

Oncologists have long puzzled over the fact that after cancer treatment, single cancer cells that are dispersed throughout the body – so-called disseminated tumor cells – are quick to grow and form secondary tumors called metastases in certain organs, while in other organs they metastasize more slowly, sometimes decades later. Such is the case with head and neck squamous cell carcinoma (HNSCC) cells, which remain dormant when lodged in bone marrow but rapidly form tumors when they make their way into the lungs.

A study published online October 27 by Nature Cell Biology by Bragado et al. reveals that bone marrow contains high levels of TGFß2, which activates the tumor suppressor gene p38 in tumor cells and triggers a cascade of events that renders tumor cells dormant and keeps HNSCC growth in check. In the lungs, where TGFß2 is in short supply, these cells rapidly form tumors.

The research team, led by Julio A. Aguirre-Ghiso, PhD, Associate Professor of Medicine, Hematology and Medical Oncology, and Otolaryngology at the Icahn School of Medicine at Mount Sinai, is the first to identify the role of TGFß2 in determining whether HNSCC cells will remain harmlessly dormant or behave aggressively in a given location. The study confirms a century-old theory called the “seed and soil” theory of metastasis, which suggests that a tumor cell – the seed – either sleeps or thrives within the unique environment of each organ – the soil.

“Our study provides critical evidence to explain why tumor cells gain a firm foothold in certain organs but not in others, where they can remain inactive for long periods of time,” explained Dr. Aguirre-Ghiso.

Approximately 80 percent of the animal models the researchers studied contained disseminated HNSCC cells in the lungs, while less than 30 percent contained tumor cells in the bone marrow. After removing the primary tumors, the number of disseminated tumor cells in the bone marrow remained the same for several weeks (equivalent to ~ 3 years in humans). However, the number of tumor cells in the lungs increased shortly after the tumors were removed, suggesting that conditions within each organ had a long-lasting effect on the cells’ behavior.

In addition, the researchers discovered that lowering TGFß2 or p38 levels awakened dormant cells and fueled metastatic growth throughout the body.

These findings may have implications for estrogen-positive breast tumor cells, which have a similar genetic signature to that of dormant HNSCC cells.

“Our study is the first to identify specific characteristics found in cancer cells as well as in the microenvironment in which they are found that determine whether they will metastasize rapidly, posing a new threat to the patient, or will remain dormant for a period of time,” said Dr. Aguirre-Ghiso. “Eventually, we may be able to predict, based on markers detected in disseminated tumor cells and/or in the microenvironment, which patients have a dormant disease and which ones will need more aggressive treatment. This information may also lead to the development of new drugs that mimic the pathways that prevent tumor cells from metastasizing.”

About the Mount Sinai Health System
The Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven member hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services—from community-based facilities to tertiary and quaternary care.

The System includes approximately 6,600 primary and specialty care physicians, 12-minority-owned free-standing ambulatory surgery centers, over 45 ambulatory practices throughout the five boroughs of New York City, Westchester, and Long Island, as well as 31 affiliated community health centers. Physicians are affiliated with the Icahn School of Medicine at Mount Sinai, which is ranked among the top 20 medical schools both in National Institutes of Health funding and by U.S. News & World Report.

For more information, visit Mount Sinai on the web, Facebook, Twitter or YouTube.

Read the full story at http://www.prweb.com/releases/2013/10/prweb11271629.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. “Get the Best Grades With the Least Amount of Effort” Instructs People How to Get Good Grades Easily and Quickly – V-kool
2. Two Mount Sinai Physicians Elected To The Institute Of Medicine
3. New Research from Mount Sinai on Alcohol Could Spur Development of Antidote
4. Mount Sinai finds value and limitations of patient assistance programs for women with breast cancer
5. Mount Sinai Researchers Find Value -- and Limitations -- of Patient Assistance Programs for Women with Breast Cancer
6. Mount Sinai Queens Breaks Ground for Expansion Project
7. Invisalign Dentist, Grant Road Dental, to Host Invisalign Day in Mountain View, CA. on October 1, 2013
8. Head Mounted Display (HMD, Helmet Mounted Display, Head Mounted Display/Computing) Market (2012 - 2017) – New Report by MarketsandMarkets
9. Wright Conserve Hip Replacement Lawsuits Continue to Mount in Federal Litigation, Bernstein Liebhard LLP Reports
10. Avenidas to Host 10th Annual Caregiver Conference in Mountain View, CA
11. NIH Grant to support Mount Sinai Research Program to Create Biological Network Model of Alzheimer’s Disease in partnership with New York Stem Cell Foundation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... ... 2016 , ... Comfort Keepers® of San Diego, CA is excited to announce ... program to drive cancer patients to and from their cancer treatments. Comfort Keepers ... of life and ongoing independence. Getting to and from medical treatments is one ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
(Date:6/24/2016)... Arizona (PRWEB) , ... June 24, 2016 , ... ... practice, is supporting the upcoming 2016 Miss Arizona pageant as its official Medspa ... serves Scottsdale, Tempe, Mesa, and Chandler, Arizona. , Dr. Olson says the ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016 Dublin ... addition of the " Global Markets for Spectroscopy ... This report focuses on the ... review, including its applications in various applications. The report ... includes three main industries: pharmaceutical and biotechnology, food and ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016 /PRNewswire/ ... pulmonary function testing company, is now able to perform sophisticated lung ... ndd Medical Technologies , Inc. Patients are ... labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients like ... any needed testing done in the comfort of her own home. ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
Breaking Medicine Technology: